References (Chapter 3)< Back to search results
- Difficulty Introductory
References for the section “More is not necessarily better”:
1 Crile G. A plea against blind fear of cancer. Life, 31 October 1955, pp128-32.
2 Baum M, Houghton J. Contribution of randomised controlled trials to understanding and management of early breast cancer. BMJ 1999;319:568-71.
3 Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. New England Journal of Medicine 2002;347:1227-32.
4 Baum M. Breast beating: a personal odyssey in the quest for an understanding of breast cancer, the meaning of life and other easy questions. London: Anshan, 2010.
5 Japanese Breast Cancer Society. Results of questionnaires concerning breast cancer surgery in Japan 1980-2003. Breast Cancer 2005;12(1).
6 Early Breast Cancer Trialists’ Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. New England Journal of Medicine 1988;319:1681-92.
7 Clinical Trial Service Unit. Accessed 17th January 2012.
8 The Cochrane Collaboration. Accessed 17th January 2012.: .
9 Kolata G, Eichenwald K. Health business thrives on unproven treatment, leaving science behind. New York Times Special Report, 2 October 1999.
10 Farquhar C, Marjoribanks J, Basser R, et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD003139.
11 Farquhar C, Marjoribanks J, Basser R, et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD003142.
12 Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER-2-positive breast cancer. New England Journal of Medicine 2005;353:1659-72.
13 Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2-positive breast cancer. New England
Journal of Medicine 2005;353:1673-84.
14 Carlson GW, Woods WC. Management of axillary lymph node metastasis in breast cancer: making progress. JAMA 2011;305:606-7.